linjc16/ctgov huggingface dataset:
The Status of Asthma in the Korean Military Personnel

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the status of allergic diseases in the Korean military personnel.

Detailed Description
-----------------
ISAAC (International Study of Asthma and Allergies in CHildhood) questionnaires are sent to military personnel in the republic of Korea. Military personnel are randomly selected representative of the number of soldiers in each area. We perform methacholine provocation test and MAST for current wheezer after informed consents.

Official Title
-----------------
The Status of Asthma in the Korean Military Personnel

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Korean military personnel who can respond questionnaire Exclusion Criteria: Person who refuse to participate in this study
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Soldiers<br>Soldiers: The soldiers who respond the questionnaires | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Allergic rhinitis, Military
Randomized Trial Of Platelet Transfusion Policies After Blood Stem Cells Transplantation In Young Children: Reduction Of Number Of Single Platelet Concentrate Donors Per Child

Study Overview
=================
Brief Summary
-----------------
Randomized Trial Of Platelet Transfusion Policies After Blood Stem Cells Transplantation In Young Children: Reduction Of Number Of Single Platelet Concentrate Donors Per Child

Official Title
-----------------
Randomized Trial Of Platelet Transfusion Policies After Blood Stem Cells Transplantation In Young Children: Reduction Of Number Of Single Platelet Concentrate Donors Per Child

Conditions
-----------------
Children Treated With High-Dose Chemotherapy (HDC) Followed by Haematopoietic Stem Cell Transplantation (HSCT)

Intervention / Treatment
-----------------
* Procedure: Platelet concentrates


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children weighing 30 kg or less with a diagnosis of haematological malignancy or solid tumour, who were candidates for HSCT were eligible for inclusion in the study. Written informed consent was required from parents of eligible children. Exclusion Criteria: Children were excluded if they had a anti-HLA and/or anti-HPA antibody, if they were prior included in this study or if the parents declined to participate.

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Platelet concentrates|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary end point of the study was tocompare the number of platelet concentrates donors who were implicated in platelet transfusion supportive after HSCT. |  |  |
Cost- Effectiveness Study of Brief Interventions for Mood and Anxiety Disorders

Study Overview
=================
Brief Summary
-----------------
This study compares both clinical effectiveness and cost-effectiveness of a brief, intensified therapy and diagnostic method for patients with mood and/or anxiety disorders with Treatment As Usual (TAU) at five outpatient Mental Healthcare Centers in the Netherlands.

Official Title
-----------------
A Efficacy and Cost-effectiveness Study of a Brief Interventions for Mood and Anxiety Disorders: Brief Intake, Treatment and Routine Outcome Monitoring (ROM)

Conditions
-----------------
Depressive Disorder, Anxiety Disorder

Intervention / Treatment
-----------------
* Other: Cognitive behavioral treatment/farmacotherapy intervention
* Other: Treatment As Usual


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male of female adolescents Adolescents aged between 18 to 65 year Adolescents main complaint: Mild to moderate anxiety and/or mood disorders with or without psychiatric and/or somatic co-morbidity Adolescents with proper understanding of the Dutch language. Exclusion Criteria: Adolescents with current psychotic or bipolar traits, Adolescents with homicidal or suicidal risk Adolescents with severe social disfunctioning No proper understanding of the Dutch language

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cognitive behavioral treatment/farmacotherapy intervention<br>Brief intervention; intake, cognitive behavioral treatment/farmacotherapy (SSRI) and ROM | Other: Cognitive behavioral treatment/farmacotherapy intervention<br>* Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM<br>|
| Other: Treatment As Usual<br>Control group, TAU | Other: Treatment As Usual<br>* Other: Treatment As Usual<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effectiveness of the intervention | Effectiveness of the intervention is investigated by the main questionnaires: Web Screening Questionnaire (WSQ) and Brief Symptom Inventory (BSI) as conducted by ROM | approximately 3 years (start: march 2010). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cost-effectiveness intervention | Cost-effectiveness is explored by an open questionnaire Trimbos/iMTA Questionnaire for Cost Associated with Psychiatric Illness (TIC-P). Additionally patient and therapist satisfaction about the intervention is explored. | approximately 3 years (start: march 2010). |
Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)

Official Title
-----------------
A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Conditions
-----------------
Crohn's Disease

Intervention / Treatment
-----------------
* Drug: Adalimumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Males and females between the ages of 18 and 75 who are diagnosed with moderate to severe Crohn's Disease defined by a CDAI score of >= 220 and <= 450, normal laboratory parameters, are willing and able to give informed consent, and are able to self-inject or have a designee or healthcare professional who can inject the study medication. Exclusion: History of certain types of cancer, diagnosis of ulcerative colitis, female or breast feeding subjects, surgical bowel resection(s) with in the past 6 months, history of listeria, human immunodeficiency virus (HIV), central nervous system demyelinating disease or untreated TB, history of a poorly controlled medical condition, unsuccessful response to infliximab or any anti-TNF agent use in the past.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Adalimumab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical remission (CDAI<150). |  | 56 weeks |
Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small cell lung carcinoma. This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where it is given weekly. The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma.

Official Title
-----------------
A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol.

Conditions
-----------------
Carcinoma, Non-Small-Cell Lung

Intervention / Treatment
-----------------
* Drug: Paclitaxel and carboplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Confirmation of non-small cell bronchogenic carcinoma (epidermoid, squamous, adeno, large cell anaplastic carcinoma, but no small cell or carcinoid) must be histologically or cytologically confirmed. No prior antineoplastic chemotherapy, hormonal therapy or therapy with biological response modifiers No previous irradiation to the only area of measurable disease. Exclusion Criteria: Past or current history of neoplasm other than the entry diagnosis. Exceptions are curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or other cancers treated by surgery or radiation with a disease free survival longer than 5 years. Patients who have undergone surgery less than 3 weeks prior to enrollment. History of serious cardiac disease not adequately controlled. Patients with serious active infections or other serious underlying medical condition. Uncontrolled diabetes mellitis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Paclitaxel and carboplatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
This study will evaluate combination chemotherapy for patients with extensive stage small cell lung cancer combined with the potentially useful growth inhibiting effects of Gleevec.

Detailed Description
-----------------
Upon determination of eligibility, all patients will be receive: Irinotecan + Carboplatin + Imatinib

Official Title
-----------------
Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Drug: Imatinib
* Drug: Irinotecan
* Drug: Carboplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be included in this study, you must meet the following criteria: Small cell lung cancer with extensive stage disease confirmed by biopsy Measurable or evaluable disease Ability to perform activities of daily living with minimal assistance Adequate bone marrow, liver and kidney No active brain metastasis. No previous chemotherapy or radiation therapy Give written informed consent. Exclusion Criteria: You cannot participate in this study if any of the following apply to you: Limited stage disease (includes IA, IB, IIA, IIB, and IIIA) Active brain metastasis Age < 18 years old History of a prior malignancy within three years Women pregnant or lactating. Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Imatinib|nan|
|Drug: Irinotecan|nan|
|Drug: Carboplatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall response rate |  |  | 
| Response duration |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to progression |  |  | 
| Overall toxicity |  |  |
Neuroendocrine Dysfunction in Traumatic Brain Injury: Correlation With Cognitive Dysfunction and Repair

Study Overview
=================
Brief Summary
-----------------
Traumatic Brain Injury (TBI) is a neurologic disorder cuased by physical trauma to the brain. Neuroendocrine abnormalities in these patients have been reported, including central hypogonadism within hours of the insult and eventual recovery of the hypothalamic-pituitary-gonadal axis with recovery of cognitive function to baseline. This pilot study will measure hormonal level of neuroendocine function at the time of TBI and various time points during recovery.

Conditions
-----------------
Traumatic Brain Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male subjects having had a recent traumatic brain injury. Exclusion Criteria: Currently receivng sex steroids, glucocorticoids, or have an inability to complete the neurobehavioral assessment.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Edessy Stem Cell Score (ESS), Endometrium, Endometrioma

Study Overview
=================
Brief Summary
-----------------
Purpose of this study is to evaluate stem cell expression (SCE) in endometriotic (E) and non endometriotic ovarian and endometrial tissues.

Detailed Description
-----------------
This study was conducted on 40 women at Al-Azhar University Hospitals. They are divided into two equal groups, group 1 with ovarian endometrioma and group 2 with normal ovary. Ovarian and endometrial samples were evaluated by hematoxlin & eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE. Evaluation of IH parameters revealed that the most important factors for evaluating SC were arranged as score ( Edessy Stem Cell Score=ESS).

Official Title
-----------------
Edessy STEM CELL SCORE (ESS), Endometrium, Endometrioma

Conditions
-----------------
Endometriosis, Ovarian

Intervention / Treatment
-----------------
* Procedure: Ovarian and endometrial samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20 to 40 years and did not receive hormonal treatment for three month Exclusion Criteria: Diabetes mellitus, cardiovascular and kidney diseases, adenomyosis, Uterine fibroid Endometrial carcinoma and Poly cystic ovary

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ovarian endometrioma<br>Ovarian and endometrial samples | Procedure: Ovarian and endometrial samples<br>* Ovarian and endometrial samples were evaluated by hematoxlin &amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE<br>|
| Experimental: normal ovary<br>Ovarian and endometrial samples | Procedure: Ovarian and endometrial samples<br>* Ovarian and endometrial samples were evaluated by hematoxlin &amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Edessy Stem Cell Score (ESS) | ESS Intensity of stem cell marker: Negative to mild =0, Moderate =1, Strong =2 Percentage of stained cells: 0 =0, 0-50%= 1, >50-100% =2. Focality : None =0, Focal =1, Diffuse= 2 Distribution: None= 0, Epithelial or mesenchymal= 1, Epithelial and mesenchymal= 2. Localization of positive stained cell: None=0, Cytoplasmic or nuclear =1, Cytoplasmic and nuclear= 2 | 1 week |
A Study on Nutrition Support in Adult Patients With Severe Burns

Study Overview
=================
Brief Summary
-----------------
To delineate nutritional support in adults patients with severe burns to investigate associations between nutritional practice and clinical outcomes.

Conditions
-----------------
Severe Burn, Enternal Nutrition

Intervention / Treatment
-----------------
* Other: enteral nutrition and parenteral nutrition


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients were at least 18 years of age Patients were expected to survive more than 48 hours. Exclusion Criteria: irreversible disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: enteral nutrition and parenteral nutrition|In the treatment of the burned patients injured,data on nutritional support and patient's outcomes were collected and analyzed.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality at 28 days | Daily data were recorded for a maximum of 28 days per patient. Patients alive in hospital at the 28th day or discharged prior to 28 days were considered to be survivors. | 28days |
Efficacy of Novel Edible Gel-based Artificial Saliva in Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether continuous use of edible, gel-based artificial saliva in cancer patients with dry mouth problems will reduce signs and symptoms of dry mouth and improve quality of patients' saliva.

Official Title
-----------------
Efficacy Study of Novel Edible Gel-based Artificial Saliva in Xerostomic Cancer Patients

Conditions
-----------------
Cancer of Head and Neck, Cancer, Radiation-induced Xerostomia, Dry Mouth

Intervention / Treatment
-----------------
* Other: Gel-based artificial saliva


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cancer patients who receive/ had received radiotherapy and/or chemotherapy and have dry mouth problems Exclusion Criteria: mucositis more than grade 1 cannot perform oral intake of gel-based artificial saliva eg. aspirate

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Gel-based artificial saliva<br>Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks | Other: Gel-based artificial saliva<br>* Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth. Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks.<br>* Other names: Oral moisturizing jelly;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in subjective dry mouth score | The outcome measure (subjective dry mouth score) will be measured before and 2 and 4 weeks after continuous usage of edible gel-based artificial saliva (30-50 ml/day for at least 5 days per week) | baseline, 2 weeks and 4 weeks after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in objective dry mouth score | The outcome measure will be measured before and 2 and 4 weeks after continuous usage of edible gel-based artificial saliva (30-50 ml/day for at least 5 days per week) | Baseline, 2 week and 4 weeks after the start date | 
| Changes in salivary pH | The outcome measure will be measured before and 2 and 4 weeks after continuous usage of edible gel-based artificial saliva (30-50 ml/day for at least 5 days per week) | Baseline, 2 weeks and 4 weeks after the start date | 
| Changes in salivary buffering capacity | The outcome measure will be measured before and 2 and 4 weeks after continuous usage of edible gel-based artificial saliva (30-50 ml/day for at least 5 days per week) | Baseline, 2 weeks and 4 weeks after the start date |